Scynexis pulls vaginal infection tablet from shelves, pauses ongoing trials on the heels of contamination risk concerns
Scynexis pulled its vaginal infection drug Brexafemme (ibrexafungerp) from the market and placing a temporary hold on ongoing clinical trials due to contamination risk issues …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.